Endocrine Abstracts

Background: Increased liver and cardiac fat are common in patients with type 2 diabetes mellitus (T2DM) and associated with increased risc for liver fibrosis and cardiovascular events. The effect of a DPP-4 inhibitor vildagliptin on the fat content of the liver and heart has not been evaluated.Methods: A total of 40 patients, 20 males and 20 females, treated at our diabetes metabolic unit of the Medical University of Vienna with gliptins underwent magnet...